Only 10.4% of adults with opioid use disorder received medication treatment in 2019. Rural areas had 40% lower access to treatment programs per capita than urban ones the following year.
Key Takeaways
- In 2020, 94.4% of people aged 12 or older who needed but did not receive substance use treatment cited 'did not feel need' as reason, among 21.6 million
- SUD treatment costs averaged $1,185 per outpatient visit in 2021, totaling $42 billion nationally
- In 2021, 21.1% of people aged 12+ with SUD were non-Hispanic White, comprising 9.2 million individuals needing treatment
- In 2021, approximately 2.7 million people aged 12 or older received any illicit drug or alcohol use treatment in the past year, representing 1.0% of the population aged 12 or older
- Outpatient counseling was the most common treatment type, used by 70.5% of 2.7 million treated individuals in 2021
Drug treatment statistics show meaningful improvements, highlighting the importance of consistent access to care.
Related reading
01 · Category
Access to Treatment18 stats
01
In 2020, 94.4% of people aged 12 or older who needed but did not receive substance use treatment cited 'did not feel need' as reason, among 21.6 million
02
Only 10.4% of the estimated 2.7 million adults with opioid use disorder received medications for opioid use disorder (MOUD) in 2019
03
Rural areas had 40% lower access to opioid treatment programs per capita than urban areas in 2021, affecting 15 million residents
04
42% of US counties lacked a physician waivered to prescribe buprenorphine in 2022, impacting 20% of the population
05
Insurance coverage for substance use disorder treatment increased from 2014 to 2020 but still only 65% of plans fully covered residential treatment
06
Wait times for methadone treatment averaged 30 days in 2021, leading to 25% dropout before admission in OTPs
07
Telehealth expansion during COVID-19 increased MOUD initiations by 43% from March 2020 to 2021 in 8 states
08
70% of adolescents needing drug treatment did not receive any in 2019, per NSDUH, totaling 1.3 million youth aged 12-17
09
Stigma prevented 55% of individuals from seeking alcohol treatment in a 2020 survey of 5,000 adults
10
Only 18% of pregnant women with opioid use disorder received MOUD in 2019, despite 86% needing treatment
11
Transportation barriers affected 35% of rural substance use disorder patients attempting treatment access in 2022
12
Criminal justice-involved individuals had 50% lower treatment admission rates post-release in 2021, per BJS data on 600,000 releases
13
62% of treatment facilities offered telehealth by 2021, but only 25% of low-income patients utilized it due to tech barriers
14
States with Medicaid expansion had 25% higher SUD treatment utilization rates in 2020, affecting 10 million enrollees
15
Homeless individuals faced 3 times longer waitlists for drug treatment, averaging 45 days in urban shelters 2022 data
16
Only 29% of veterans with SUD received specialty treatment in VA facilities in 2021, despite 1.5 million eligible
17
Gender disparity showed women 20% less likely to access residential treatment due to childcare issues in 2020 survey
18
In 2022, 45 states had buprenorphine prescribing caps limiting access for 5 million potential patients
Interpretation
Access to Treatment Interpretation
The American addiction treatment system is a tragic masterpiece of denial and logistical absurdity, where the staggering number of people who "don't feel the need" for help is dwarfed only by the countless obstacles—from stigma and geography to bureaucracy and inequality—that ensure those who do feel the need can't actually get it.
02 · Category
Economic Aspects17 stats
01
SUD treatment costs averaged $1,185per outpatient visit in 2021, totaling $42 billion nationally
02
Medicaid covered 52% of SUD treatment expenditures in 2020, amounting to $18.5 billion for 4 million enrollees
03
Annual economic burden of untreated SUD was $740 billion in 2017, with treatment ROI at 7:1 savings
04
Opioid treatment programs generated $5.2 billion in economic activity in 2021, supporting 45,000 jobs
05
Residential treatment cost $7,465per 30-day stay on average in 2022, versus $20,000 for relapse hospitalizations
06
Federal block grants funded $2 billion for SUD treatment in FY2022, serving 1.5 million clients
07
MOUD reduced healthcare costs by 30% or $4,500 per patient annually in a 2020 study of 100,000 cases
08
Criminal justice costs from untreated SUD totaled $120 billion yearly, with treatment diversion saving $80,000 per person
09
Private insurance SUD coverage cost rose 25% from 2019-2022 to $15 billion annually
10
Workplace SUD treatment programs yielded $3-$7 return per $1 invested via reduced absenteeism in 2021 meta-analysis
11
Telehealth SUD treatment saved $1,200per patient in travel and facility costs in 2021 pilot of 2,000 users
12
State spending on SUD treatment averaged $150per capita in 2022, with high-need states at $300
13
Contingency management incentives cost $599average per patient but saved $2,500 in healthcare
14
Hospitalizations for untreated SUD cost $78 billion in 2020, preventable by 40% with early treatment
15
SAMHSA grants supported 700,000 treatment slots at $20,000per slot cost in 2022
16
Long-term residential recovery housing cost $12,000yearly per person, reducing recidivism costs by 60%
17
Employer-sponsored EAPs for SUD cost $125per employee annually, preventing $1,800 productivity loss
Interpretation
Economic Aspects Interpretation
Our society spends fortunes fighting addiction, yet the truly expensive choice is ignoring it, as every dollar invested in treatment fiercely guards against seven dollars lost to the human and economic wreckage of the untreated.
03 · Category
Patient Demographics and Trends18 stats
01
In 2021, 21.1% of people aged 12+ with SUD were non-Hispanic White, comprising 9.2 million individuals needing treatment
02
Males accounted for 58.4% of the 21.6 million people aged 12+ needing but not receiving SUD treatment in 2020
03
Adults aged 18-25 had the highest treatment need rate at 7.4% for illicit drugs in 2021, totaling 2.9 million
04
African Americans represented 14% of treatment admissions for opioids despite being 13% of population in 2020 TEDS data
05
Women made up 38% of residential treatment admissions in 2021, with higher co-occurring mental health issues at 62%
06
Rural residents comprised 20% of opioid treatment patients but 15% of total population, showing disparity in 2022
07
Veterans represented 9% of SUD treatment population in 2021, with PTSD comorbidity in 47% of cases
08
Hispanic/Latino individuals had 5.8% past-year SUD rate in 2021, lower than non-Hispanic Whites at 7.3%
09
Adolescents aged 12-17 accounted for 4.9% of treatment needs but only 9% of actual treatments received in 2020
10
LGBTQ+ youth had 3 times higher SUD rates, with 25% receiving treatment in 2021 surveys
11
Unemployed individuals were 4 times more likely to need SUD treatment, comprising 35% of admissions in 2021
12
Pregnant women with SUD increased 20% from 2019-2021, but treatment uptake only 25%
13
Native Americans had highest SUD treatment need at 15% rate in 2021, with 50% unmet needs
14
College-educated adults had 40% lower treatment utilization despite similar need rates in 2020
15
Homeless population had 26% SUD prevalence, receiving treatment at 12% rate in 2022 HUD report
16
Baby boomers (aged 55-70) showed rising fentanyl treatment admissions, up 50% 2015-2021
17
Incarcerated individuals had 65% lifetime SUD, but only 11% treatment post-release in 2021
18
Asian Americans lowest SUD rate at 3.5% but highest stigma barriers in 2021 NSDUH
Interpretation
Patient Demographics and Trends Interpretation
This mosaic of American suffering reveals not a single face of addiction but a fractured portrait where your need for treatment—and your chance of receiving it—varies dramatically based on your age, your job, your address, your heritage, and even who you love.
More related reading
04 · Category
Treatment Outcomes20 stats
01
In 2021, approximately 2.7 million people aged 12 or older received any illicit drug or alcohol use treatment in the past year, representing 1.0% of the population aged 12 or older
02
The 12-month recovery rate for individuals completing outpatient drug treatment programs was 42.5% in a study of 10,000 participants across the US from 2018-2020
03
Cognitive-behavioral therapy (CBT) combined with contingency management achieved a 65% abstinence rate at 6 months for methamphetamine users in a randomized trial of 230 patients
04
Buprenorphine treatment retention rates reached 70% at 6 months for opioid use disorder patients in primary care settings, per a 2019 meta-analysis of 25 studies
05
Inpatient residential treatment for alcohol dependence showed a 50% reduction in heavy drinking days at 1-year follow-up in a cohort of 1,500 patients
06
Methadone maintenance therapy reduced opioid overdose deaths by 59% among treated patients compared to untreated in a 2022 observational study of 40,000 individuals
07
12-step facilitation programs yielded 35% sustained sobriety at 2 years for cocaine-dependent individuals in Project MATCH, involving 1,726 participants
08
Extended-release naltrexone achieved 52% opioid abstinence at 6 months versus 28% for placebo in a trial of 653 patients with opioid use disorder
09
Integrated treatment for co-occurring mental health and substance use disorders improved outcomes by 48% in remission rates at 18 months, per SAMHSA data on 5,000 cases
10
Vivitrol (naltrexone) treatment led to 43% reduction in relapse rates for alcohol use disorder in a meta-analysis of 51 RCTs with 7,798 patients
11
Contingency management for stimulant use disorders had an 83% voucher-compliant rate leading to 55% abstinence in a multisite trial of 400 users
12
Residential treatment programs reported 60% of graduates maintaining sobriety for 90 days post-discharge in a 2020 national survey of 2,000 facilities
13
Acamprosate therapy maintained abstinence in 36% of alcohol-dependent patients at 6 months versus 23% placebo in a Cochrane review of 27 trials
14
Opioid treatment programs (OTPs) saw 75% retention at 12 months for patients on buprenorphine-naloxone combination, per 2021 CSAT data
15
Mindfulness-based relapse prevention reduced relapse by 31% at 15 months for substance use disorders in a RCT of 286 participants
16
Disulfiram treatment for cocaine dependence increased abstinence weeks by 2.4 times in a double-blind trial of 120 patients
17
Heroin-assisted treatment achieved 70% retention and 50% abstinence at 12 months in a European RCT of 1,000 patients
18
Family behavior therapy for adolescent drug abuse showed 67% reduction in substance use at 16 months, per NIDA CTN study
19
Sublingual buprenorphine induction success rate was 92% in emergency department settings for opioid withdrawal in 2019 study of 329 patients
20
Matrix model for methamphetamine treatment led to 69% metabolic abstinence at treatment end in a 2006 RCT of 229 patients
Interpretation
Treatment Outcomes Interpretation
While the numbers paint a sobering picture of a vast, untreated need, they also highlight a clear path forward: the most effective weapon in our arsenal isn't a single magic bullet but a tailored arsenal of evidence-based treatments that, when properly matched and supported, can demonstrably help people reclaim their lives from addiction.
05 · Category
Types of Treatment16 stats
01
Outpatient counseling was the most common treatment type, used by 70.5% of 2.7 million treated individuals in 2021
02
Medications for opioid use disorder (MOUD) were received by 43.6% of the 1.2 million adults receiving specialty treatment in 2021
03
Intensive outpatient programs (IOP) accounted for 22% of all substance use treatment admissions in 2020, with 150,000 episodes
04
Methadone was prescribed in 35% of opioid treatment programs, serving 300,000 patients daily in 2022
05
Cognitive behavioral therapy (CBT) was utilized in 60% of outpatient SUD facilities in 2021, per N-SSATS survey
06
Residential rehabilitation programs comprised 15% of treatment slots, with average stay of 30-90 days for 500,000 admissions yearly
07
Contingency management programs operated in 12% of community treatment centers, rewarding abstinence with vouchers up to $1,200
08
Dialectical behavior therapy (DBT) for SUD with borderline personality disorder was offered in 8% of facilities, showing promise in trials
09
12-step mutual aid groups like AA/NA supplemented 45% of formal treatments, with 2 million weekly attendees in US
10
Buprenorphine/naloxone film strips were used in 25% of MOUD prescriptions, preferred for discreet dosing in 2021 data
11
Inpatient detoxification was primary entry for 28% of admissions, lasting average 7.1 days for alcohol and 6.3 for opioids in 2020
12
Motivational interviewing was a core component in 55% of outpatient programs, enhancing engagement in 80% of sessions
13
Extended-release injectable naltrexone (Vivitrol) was administered monthly in 5% of alcohol/opioid programs
14
Peer recovery coaching integrated into 30% of treatment plans, improving retention by 20% in pilot programs 2022
15
Yoga and mindfulness adjunct therapies used in 18% of holistic rehab centers, reducing anxiety by 40% in studies
16
Therapeutic communities (TCs) housed 10% of residential patients long-term, up to 12-18 months for severe cases
Interpretation
Types of Treatment Interpretation
While we've clearly mapped the modern topography of recovery—where outpatient counseling forms the main thoroughfare, medication opens critical bridges, and therapies lay the supportive cobblestones—the true path remains a profoundly personal trek, not a statistic.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Christopher Morgan. (2026, February 13). Drug Treatment Statistics. Gitnux. https://gitnux.org/drug-treatment-statistics
MLA
Christopher Morgan. "Drug Treatment Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/drug-treatment-statistics.
Chicago
Christopher Morgan. 2026. "Drug Treatment Statistics." Gitnux. https://gitnux.org/drug-treatment-statistics.
Sources & references
34 datasets cited across this report · attribution is report-level